



HAL
open science

Cancer-on-chip technology: current applications in major cancer types, challenges and future prospects

Zakaria Baka, Marie Stiefel, Agathe Figarol, Claire Godier, Abhik Mallick, Olivier Joubert, Nureddin Ashammakhi, Eric Gaffet, Halima Alem

► **To cite this version:**

Zakaria Baka, Marie Stiefel, Agathe Figarol, Claire Godier, Abhik Mallick, et al.. Cancer-on-chip technology: current applications in major cancer types, challenges and future prospects. *Progress in Biomedical Engineering*, 2022, 4 (3), pp.032001. 10.1088/2516-1091/ac8259 . hal-03813126

HAL Id: hal-03813126

<https://hal.science/hal-03813126>

Submitted on 13 Oct 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Cancer-on-chip technology: current applications in major cancer types, challenges and future prospects.

Zakaria Baka^a, Marie Stiefel^a, Agathe Figarol^{a,b}, Claire Godier^a, Olivier Joubert^a, Nureddin Ashammakhi^{c,d}, Eric Gaffet^a, Halima Alem^{a,e}

^aUniversité de Lorraine, CNRS, IJL, F-54000 Nancy, France.

^bUniversity Bourgogne Franche Comté, FEMTO ST Institute, CNRS, UMR 6174, F-25000 Besançon, France

^c Department of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, California, USA

^d Department of Biomedical Engineering, College of Engineering, Michigan State University, Michigan, USA

^e Institut Universitaire de France

Abstract

Conventional 2D cell cultures are widely used for the development of new anticancer drugs. However, their relevance as *in vitro* models is increasingly questioned as they are considered too simplistic compared to complex, three-dimensional *in vivo* tumors. Moreover, animal experiments are not only costly and time-consuming, but also raise ethical issues and their use for some applications has been restricted. Therefore, it becomes crucial to develop new experimental models that better capture the complexity and dynamic aspects of *in vivo* tumors. New approaches based on microfluidic technology are promising. This technology has indeed been used to create microphysiological systems called “organ-on-chip” (OOC) which simulate key structural and functional features of human tissues and organs. These devices have further been adapted to create cancer models giving rise to the “cancer-on-chip” (COC) concept. In this review, we will discuss the main COC models described so far for major cancer types including lung, prostate, breast, colorectal, pancreatic, and ovarian cancers. Then, we will highlight the challenges that this technology is facing and the possible research perspectives that can arise from them.

Key words: Cancer-on-chip (COC), *in vitro* tumor models, microfluidic technology, nanomedicine.

1. Introduction

Cancer is a major public health issue all over the world. According to the International Agency of Research on Cancer (IARC), over 19.3 million new cancer cases were reported and about 10 million people died of cancer in 2020¹. Moreover, cancer incidence is expected to highly increase during the next years especially in the developing countries². Developing new

anticancer therapies that are more effective with less side effects is thus becoming an emergency. Many efforts are being undertaken in this field but the failure rate of new anticancer molecules remains very high (about 90%)³. This is partly attributed to the lack of reliable preclinical models that can successfully reproduce *in vivo* drug responses⁴, complex tumor micro-environment and cancer related pathophysiological events⁵ such as cancer cell-stroma interactions, angiogenesis and metastasis. Indeed, current cancer studies are largely based on the use of two-dimensional (2D) cell culture⁶. Although easy to set up and well standardized, 2D culture models are far from reflecting the *in vivo* complex system, where cells closely interact with each other and with the extracellular matrix (ECM)⁷. Important differences can thus be noticed between *in vivo* tumors and 2D culture models where cells experience unnatural growth kinetics⁸. Moreover, it has been reported that the cytoskeleton of cells in 2D cultures undergoes specific modifications in response to the mechanical constraints imposed by the solid growing surface⁹. This may lead to an unnatural cell polarization with altered gene expression and protein synthesis⁹. Another important issue of the current preclinical practices in new drug development is the systematic and intensive use of animal experiments. Although animal models have been found to be important for assessing drug efficiency and toxicity, they have several drawbacks. Besides being costly and time consuming, they have important anatomic, physiologic and genetic differences from the human body¹⁰. Ethical issues related to animal use have also to be considered. For circumventing these problems and having more reliable results in early stages drug development, researchers have been seeking to develop new preclinical models that can better simulate physiological and pathophysiological processes taking place in the human body. Three dimensional (3D) cell culture approaches seem to be promising tools to reach this goal, due to their ability to better simulate cell-cell and cell-ECM interactions than classical 2D models⁹. Thus, many 3D technology based models have been reported¹¹ such as spheroids and organoids¹². These structures mimic the oxygen and nutrient gradients in human tissues but do not simulate *in vivo* dynamic conditions such as blood flow or breathing motions. Another milestone was reached through the adaptation of microfluidic technology to create microphysiological systems reproducing key dynamic phenomena of the human body¹³. The so called organ-on-chip (OOC) systems have been adapted to simulate large variety of organs and diseases including cancer (leading to the rise of the “cancer-on-chip” (COC) concept¹⁴⁻¹⁸). Many applications of these innovative technologies have been described in the literature, but

several challenges still remain to be overcome before these models enter routine use for new drug development.

The main purpose of this review is to highlight the potential of COC technology in cancer modeling and to show its ability to match the anatomic and pathophysiological features of different cancer types. We illustrate this through the analysis of COC application in the most frequent and lethal cancers¹ (lung cancer, prostate cancer, breast cancer, colorectal cancer, pancreatic cancer, ovarian cancer, brain tumors and hepatic cancers). We will first discuss the emergence and development of the OOC approach, and then describe in more details its applications in the selected cancer types. Finally, we will discuss the main challenges that arise from this technology and the resulting research opportunities.

2. Microfluidics technology

Microfluidics is defined as the science of systems that process or manipulate small quantities of fluids (10^{-9} to 10^{-18} L) using micrometer-sized channels^{19,20}. Microfluidic technology is considered as an interdisciplinary research field combining several applications in chemistry, physics, biology, medicine and other disciplines^{21,18}. In the early 1950's, microfluidics gained momentum in microanalytical, gas chromatography (GPC), high pressure liquid chromatography (HPLC) and capillary electrophoresis (CE) methods¹⁹. Since the 1990's, microfluidics has become one of the most dynamic technological areas²² with a revolutionary impact on a wide range of applications²⁰ especially in biology. Indeed microfluidic platforms enable experiments to be performed at a small scale²³ reducing the consumption of reagents and biological samples. This is particularly important when the study concerns, for example, new therapeutic molecules since they are synthesized in small and costly quantities in their early development stages. In addition, microfluidic platforms can be used to optimize biological studies by giving a more precise control over the experimental conditions such as pH, temperature, shear stress and chemical concentrations²³⁻²⁵. Recent manufacturing techniques based on the use of soft lithography can be employed to fabricate customized devices²⁶ that can generate physiological-like conditions including oxygen and nutrient gradients, fluid flow phenomena and other biochemical and biomechanical processes taking place in the human body²⁷. Besides providing precise control over experimental conditions,

microfluidic platforms also show high analytical performance²⁸ with the integration of sensors in the microfluidic device²⁹. Real-time analysis can thus be carried out. Microfluidic platforms are most commonly made from optically transparent materials such as polydimethylsiloxane (PDMS) or poly(methyl methacrylate) (PMMA), which allows performing real-time imaging procedures³⁰. Moreover, research for new materials for use in developing OOC continues^{31,32}, and smart materials with various properties such as memory³³, responsiveness³⁴, and electroconductivity³⁵ represent attractive examples that can be employed for defined applications in future.

Because of these advantages, microfluidic devices have been successfully used since the early 1990's for developing many important bio-analytical processes such as DNA analysis³⁶, immunoassays^{37,38} and protein studies^{5,39}. In the frame of cell culture and disease modelling, the use of microfluidics started to emerge in the early 2000's. For example, in 2004, Leclerc *et al.* used a PDMS device for performing a large-scale culture of hepatocytes by associating many microfluidic culture chambers⁴⁰. This device included oxygen supplying compartments which were shown to be crucial for a successful cell culture. In 2010, the emergence of the organ-on-chip (OOC) concept marked a major evolution in the use of microfluidics in the biological field. Indeed, by developing the first "lung-on-chip" device (described below), Huh *et al.*⁴¹ demonstrated that microfluidics could be used not only to culture cells in an efficient way, but also to reproduce the human physiological aspects at tissue and organ levels. From there, many research efforts have been made to fully exploit the benefits of this technology.

In the following paragraphs, we will briefly describe the most important progress done in the OOC field, and we will discuss in more detail the adaptation of this technology to the modelling of cancerous pathologies.

3. Microfluidics applications for studying cancer: cancer-on-chip (COC) concept

Cancer is a very complex process that evolves over years or decades and it involves a variety of exogenous and endogenous factors⁴². Tumor behavior in the body depends partly on the genetic characteristics of the cancer cells⁴³. However, these cancer cells interact also closely with other elements of the tumor microenvironment (TME) such as ECM molecules, stroma cells, tumor microvasculature, immune cells, and multiple signaling factors⁴⁴. These

interactions between the tumor cells and their TME strongly influence cancer pathological processes such as angiogenesis⁴⁵, metastasis⁴⁴, and drug resistance⁴⁶. It is thus crucial to take all these interactions into account to develop relevant *in vitro* models for cancer studying or anticancer drug testing.

Compared to conventional 2D cell culture, the introduction of microfluidics technology for cancer modelling has allowed to reach a higher level of complexity in creating *in vitro* systems that better mimic the *in vivo* diversity of the tumor microenvironment. This technology makes it possible to associate different cell types in a unique device with a controlled 3D architecture. More importantly, microfluidic systems can be used to reproduce *in vivo* chemical and mechanical cues that can influence the tumor behavior including

(i) oxygen and nutrient gradients,

(ii) fluid flow,

(iii) shear stress, and (iv) mechanical constraints related to physiological movements such as respiratory motions and digestive peristalsis.

For example, Yi *et al*⁴⁷. combined microfluidic technology and 3D bioprinting to develop a glioblastoma model for evaluating patient-specific cancer-cell responses to chemotherapy and radiations⁴⁷. This model consisted of a compartmentalized cancer–stroma concentric-ring structure with a peripheric vascular compartment and a central cancer compartment. Through this configuration, the authors could simulate the oxygen gradient found in *in vivo* tumors and thus reproduce *in vivo* relevant drug responses⁴⁷. Microfluidic platforms are indeed being increasingly used in oncology research⁴⁸ and their applications can be divided into three main goals:

- (i) improving our understanding of the pathophysiological processes involved in cancer and their possible therapeutic implications (cancer cell interactions with the tumor microenvironment elements^{49–51}, tumor angiogenesis^{52–54}, cancer cell invasion and metastases^{55–59}, isolation and enrichment of cancer stem cells⁶⁰).
- (ii) performing anticancer drug screening^{61–63}.
- (iii) setting-up or improving diagnosis or prognosis applications such as the detection and isolation of circulating tumor cells (CTC)^{64–66}, the analysis of tumor cell exosomes

or nucleic acids⁶⁷ and the rapid performing of immunohistochemistry staining protocols⁶⁸.

In this section, we will describe the recent advances in microfluidic tumor modelling of the most common cancers to highlight the contribution of these new models to the development of cancer research and related therapeutics.

3.1 Lung cancer

Besides being the deadliest cancer¹, lung cancer is probably one of the best examples to illustrate the interest of using microfluidic tumor-on-a-chip devices as they are particularly suitable for reproducing the lung's complex environment. As we described before, microfluidic lung models (lung-on-a-chip) have allowed to effectively reproduce the essential structural and functional features of the alveolar-capillary membrane (ACM)⁴¹ and the small airways⁶⁹. These models were further adapted to study a variety of pathophysiological aspects of lung cancer. For example, Hassel *et al.* used microfluidic models of pulmonary alveolus and small airways to study the growth and drug responses of non-small cell lung cancer (NSCLC)⁷⁰. In this study, a human NSCLC cell line was injected into the alveolus and the small airways models (Fig. 1A). It was shown that cancer cell proliferation was more important in the alveolus microenvironment, which corresponds to the *in vivo* observations. More interestingly, this study demonstrated that the application of mechanical constraints through the hollow side channels of the microfluidic alveolus model affected the cancer cell behavior. These breathing-like motions reduced the cell growth and invasion ability and modified their sensitivity to tyrosine-kinase inhibitors (TKI). While one limit of this model could be the lack of immune cells that influence NSCLC responses to anticancer therapies⁷¹, this example clearly demonstrates the interest of using microfluidic models which open new research perspectives that remain inaccessible with classical 2D or 3D cell culture platforms. Besides creating orthotopic models, microfluidic devices are also increasingly being used to study lung cancer invasion and metastasis^{72 73}, which are directly linked to its prognosis. Xu *et al.* developed a multi-organ microfluidic device to simulate lung cancer metastasis in different organs including brain, liver and bone⁷⁴. The lung-like part of the device was composed of an upper air channel and a lower medium channel separated by a microporous PDMS membrane coated

with ECM molecules. Bronchial epithelial cells and A549 cancer cells were cultured on the upper membrane surface while stromal cells (microvascular endothelial cells, fibroblasts, macrophages) were cultured on the lower membrane surface. The use of two lateral vacuum chambers allowed the application of cyclic stretching of the tissue layers. Lung chamber was connected through side channels to three other distinct chambers containing astrocytes, hepatocytes or osteoblasts to mimic lung cancer metastasis to the brain, liver or bone. After forming a primary tumor mass in the lung chamber, A549 cancer cells performed an epithelial-mesenchymal transition and spread to the secondary locations. However, one limit of this model was the absence of a functional endothelial barrier in the secondary sites making it impossible to reproduce cancer cell extravasation before creating secondary tumors. Liu *et al.* used a similar yet improved approach to investigate brain metastasis of non-small cell lung cancer⁷⁵. In this study, the lung chamber was connected to a brain mimicking organ with a functional blood-brain barrier (BBB) structure (Fig. 1B). Different lung cancer cell subpopulations with variable metastatic potential were tested in this system. Authors demonstrated that cancer cells with high brain metastatic potential overexpressed Aldo-Keto Reductase family 1B10 protein (AKR 1B10). Moreover, silencing AKR 1B10 protein expression in these cells reduced their ability to cross the BBB and hence their metastatic potential. Similar results were obtained in *in vivo* using nude mice models of brain metastatic lung cancer⁷⁵. This suggested that microfluidic devices can be reliable alternatives to *in vivo* animal experiments for lung cancer metastasis studies notably for the metastasis phenomena.




Figure 1: Examples of microfluidic OOC applications for lung cancer studies.

(A) Non-small cell lung cancer-on-a-chip: (1): Design of the chip. (2): Confocal fluorescence imaging of a cross-section in the chip showing the distribution of the different cell populations: lung cancer cells (green, anti-GFP); primary lung alveolar epithelial cells (white, antibodies against the tight junction protein ZO-1); primary lung microvascular endothelial cells (red, anti-VE-cadherin) (scale bar: 200 μm). (3): immunofluorescence imaging of NSCLC cells (green, anti-GFP) that showed slow growing rate over time when cultured in the airway mimicking chip (scale bar: 100 μm). (4): NSCLC cells (green, anti-GFP) showed different growing rates in the airway chip and the alveolus chip with and without breathing-like mechanical constraints (scale bar: 50 μm). Reproduced from ⁷⁰, with permission from Cell Press. (B) Design of the microfluidic model developed by Liu *et al.*⁷⁵ for assessing brain metastasis of lung cancer. The chip consisted of two PDMS layers and a microporous membrane. Reproduced from⁷⁵, with permission from Elsevier.

3.2 Prostate cancer

Despite its epidemiological importance, there are few examples of prostate cancer-on-chip models compared to other cancer types. In 2019, Jiang *et al.* described a simple prostate-on-chip model that reproduced the stroma-epithelial interface⁷⁶. This device consisted of two superposed PDMS channels separated by a polyester microporous membrane. Primary human prostate basal epithelial cells (PrECs) were used to form an epithelium on the lower membrane

surface while benign human prostate stromal cells (BHPPrS1s) were cultured on the upper membrane surface to form the stroma compartment. This configuration allowed paracrine communication between the cancer cells and the stroma cells while preventing direct contact between the two cell types in order to study biochemical signaling pathways in the epithelial-stroma interface. Biochemical communication between epithelial, stromal and cancer cells is a key factor in prostate cancer pathophysiology. However, biomechanical cues in the TME also need to be considered⁷⁷. For example, Ao *et al.* used a microfluidic chip to explore the impact of mechanical stress related to prostate cancer cell expansion on normal associated fibroblasts (NAFs)⁷⁸. Their system was inspired by the alveolar-capillary membrane organ-on-OOC described by Huh *et al.*⁴¹ with two superposed channels separated by a PDMS membrane which can be stretched through vacuum application on two lateral channels. Prostate NAFs were cultured on the top surface of the PDMS membrane and subjected to a consistent strain. Ao *et al.* showed that this mechanical stimulus could induce noticeable changes in NAFs behavior giving them a cancer associated fibroblasts or CAF-like phenotype⁷⁸. Compared to non-stretched NAFs, stretched NAFs produced more aligned fibronectin network and showed higher ability to direct cancer cell migration. These results suggested that mechanical stress in the tumor microenvironment associated to cancer mass expansion can play a role in activating NAFs to CAFs which may promote cancer cell migration. Again, this study⁷⁸ could not have been carried out without using a microfluidic cancer model. However, this model has focused on a very specific aspect of prostate cancer pathophysiology. It can be improved by including other TME elements such as stroma cells and functional vasculature.

3.3 Breast cancer

Many pathophysiological and therapeutic aspects of breast cancer have been investigated using microfluidic systems in five main application fields: (1) Early stages of breast cancer initiation and development⁷⁹; (2) Anticancer drug response evaluation⁸⁰ or drug delivery systems (DDS) testing⁸¹; (3) Cancer cell-fibroblast interactions⁵⁰; (4) Cell invasion⁸² and (5) the development of metastatic models⁵⁸.

Breast cancer development is a long-term and highly complex process. Typically, the development of the cancerous lesion is preceded by an overgrowth of epithelial cells lining

the mammary ducts to form a non-invasive lesion called ductal carcinoma *in situ* (DCIS)⁷⁹. Depending on several intrinsic and extrinsic factors, this non-invasive DCIS can develop into an invasive form (invasive ductal carcinoma (IDC))^{83,84}. It is therefore, crucial to understand this transition from a localized to an invasive form. In this respect, Choi *et al.* described a DCIS microfluidic model⁷⁹, consisting of two superposed culture chambers (Fig. 2A). The upper chamber simulated the ductal lumen while the lower one mimicked stromal vascular capillary. The two chambers were separated by a thin vitrified collagen membrane that simulated basement membrane. On the upper membrane surface, epithelial mammary cells were first cultured to form an epithelium. Then, DCIS spheroids obtained from a 96-well hanging drop plate were seeded in this epithelial layer to mimic neoplastic masses. On the lower membrane surface, a fibroblast containing collagen gel was deposited to reproduce the stroma tissue in the mammary duct. This microfluidic model was then used to assess efficacy and toxicity of an anticancer drug (Paclitaxel) which was injected in the lower chamber to mimic intravenous administration. Although this model is a good representation of DCIS, it was only maintained in culture for one week. This is a very short time-window considering that DCIS can progress over years *in vivo* before potentially becoming a malignant tumor⁸⁵. Devadas *et al.* described another microfluidic model of mammary gland to study complex interactions between epithelial and endothelial cells to better understand the evolution and propagation of cancerous lesions⁸⁴. This model was composed of four microfluidic culture units in a 2X2 disposition (Fig. 2B). Each unit was formed of two parallel microfluidic channels connected by three migration ports. A partially polymerized Matrigel and collagen hydrogel was injected into the microfluidic channels then gently aspirated to form cylindrical lumens for the simulation of vascular and ductal lumens. The endothelial mimicking lumen was lined with endothelial cells. In the epithelial mimicking channel, three kinds of breast epithelial cells were tested, a non-cancerous breast epithelial line (MCF-10A), a non-invasive cancerous line (MCF-7) and a highly metastatic line (MDA-MB-231) (one cell type at a time in the culture unit). Using this device, it was possible to establish the migratory profile of the three breast cell lines and to show that the migration ability of MDA-MB-231 cells is potentiated when co-cultured with endothelial cells. While in this model no stroma compartment was taken into account, a complementary study was conducted by Nagaraju *et al.*⁸⁶ They focused on cancer cell intravasation into the blood stream and invasion of the surrounding stroma through the use a three layer concentric microfluidic model⁸⁶. This model comprised an inner tumor region, an

intermediate stroma region, and a peripheral vascular region where endothelial cells embedded in a fibrin gel were allowed to spontaneously form an *in vivo* like capillary network (Fig. 2C). In both tumor and stroma regions, collagen was used to mimic the ECM while fibrin hydrogel was chosen to support capillary growth and organization in the vascular area. As for the previous example, it has been shown that the number of MDA-MB-231 cells migrating into the stroma was significantly increased in systems with endothelial cells capillary networks in comparison with control systems (without endothelial cells). Moreover, in the capillary network containing system, MDA-MB-231 cells were able to reach the fibrin matrix region and to penetrate inside the vascular network (intravasation phenomenon) while in control systems, they were incapable of reaching the peripheral fibrin matrix region. Using high resolution imaging techniques, it was possible to monitor real-time interactions between endothelial and cancerous cells, while the latter attached to the endothelial wall and crossed to the vascular lumen. Interestingly, it was demonstrated that cancer cell-endothelial cell interactions also take place in the other direction. Indeed, the authors showed that the vascular network grown in co-culture with MDA-MB-231 cells was highly permeable and smaller in diameter compared to that obtained in the control endothelial cell monoculture system. On the contrary, endothelial cell co-culture with MCF-7 (non-invasive breast cancer cell line) had no impact on the vascular network morphology or function. Here also, similar observations were made in *in vivo* animal models^{86,87}. While Nagaraju *et al.* focused on the early stages of metastasis (intravasation)⁸⁶, other works have investigated more advanced stages of this highly complex process. In one example, Mei *et al.* designed a microfluidic device to elucidate the osteocytes mechanical regulation of breast cancer metastasis to the bone⁸⁸. To accomplish this, they used a two-parallel channels microfluidic device. One channel had an endothelial cell coated lumen to mimic the vascular compartment. In the other channel, MLO-Y4 osteocyte cells were seeded to create bone compartment. The two compartments were connected by lateral channels (Fig. 2D). MDA-MB-231 breast cancer cells were introduced in the vascular-like channel. Their extravasation and migration through the side channels were then monitored in different conditions. In the control group, the observation was carried out under static conditions while in the experimental group, a physiologically relevant oscillatory fluid flow (1Pa, 1Hz) was applied to MLO-Y4 cells in the bone channel to mimic shear stress conditions applied to the bone during physical activity. The results showed that mechanically stimulated osteocytes have significantly reduced extravasation potential of the breast cancer

cells (reduction in the extravasation distance and the percentage of invaded side channels). It can be seen here that the use of a microfluidic system helped to understand how physical activity could influence bone metastasis of breast cancer through the ability to reproduce physiologically relevant dynamic conditions. In breast cancer research, microfluidic devices are also investigated as drug testing platforms. They can be used either for new drug development or for therapy optimization in personalized medicine. For new drug development, they are strongly thought to be more predictive than traditional 2D cultures. For therapy optimization, they offer a considerable time-effectiveness as compared to the use of patient derived xenografts (PDX) implanted in immunodeficient animals. To demonstrate this, Lanz *et al.* used a 96-microfluidic unit system to perform anticancer drug assays on cell lines and PDX-derived cancer cells. Cells cultured in 3D conditions under continuous flow showed high viability. Moreover, these 3D cultured cells showed higher drug resistance compared to these cultured in 2D conditions⁸⁹. A more complex system was described by Predhan *et al.* who designed a vascularized perfused platform for assessing anticancer drug efficacy on non-invasive and invasive breast micro-tumor models⁹⁰. In this platform, human breast tumor-associated endothelial cells (hBTECs) were first used to create a lumenized vascular network in microfluidic channels. This vascular structure ensured the perfusion of two superposed tumor chambers connected by a vertical channel (primary and secondary tumor chambers). For tumor formation, non-invasive MCF-7 or invasive MDA-MB-231 cells were suspended with fibroblasts in a poly(ethylene glycol)-fibrinogen hydrogel precursor. The cell containing suspension was then injected into the primary tumor chamber and photo-crosslinked using visible light⁹¹ to form a “tumor-like structure”. The adaptation of the platform design made it possible to simulate two different perfusion levels (high perfusion and low perfusion level) to better capture the *in vivo* heterogeneity of different tumor regions. These platforms were then used for assessing anticancer efficacy and endothelial toxicity of two commonly used drugs (doxorubicin and paclitaxel)⁹⁰. This demonstrates the possibility of using microfluidic devices for investigating both therapeutic and side effects of anticancer drugs. Moreover, this model shows numerous other advantages including the presence of a functional vascular network. The tumor structures could also be maintained in culture over a relatively long period of 28 days. Nevertheless, it remains far from reproducing all the complexity of an *in vivo* breast tumor, notably because of the absence of key TME actors such as adipocytes and immune cells^{92,93}.




Figure 2: Application of COC technology for breast cancer modelling.

(A) Early stage breast cancer model. Ductal adenocarcinoma *in situ* (DCIS) spheroids were grown in the epithelized upper surface of a membrane. A fibroblast containing extracellular matrix (ECM) hydrogel was applied in the bottom surface of the membrane to mimic the stromal compartment. Reproduced from⁹⁴, with permission from Royal MDPI. (B) Device to study the interplay between cancer cells and endothelial cells in breast cancer. It was composed of 4 microfluidic units in a 2X2 configuration. Each unit comported 2 channels connected by 3 migration ports. Reproduced from⁸⁴, with permission from AIP Publishing. (C) Three-compartment microfluidic chip to study breast cancer cell dissemination in the stroma and intravasation into the vascular stream. Reproduced from⁹⁵, with permission from Elsevier. (D) Mei *et al.*⁸⁸ used a microfluidic device to simulate bone metastasis of breast cancer and the regulating role of osteocytes. The device they developed comprised 6 units. Each unit was composed of one vascular compartment and one osteocyte compartment. The two compartments were connected by side channels.

3.4 Colorectal cancer

For colorectal cancer (CRC) research, the potential of microfluidic approaches has been mainly exploited in the isolation, enrichment and analysis of circulating tumor cells for diagnosis and prognosis purposes^{96 97 98}. Conversely, only few tumor⁹⁹ and metastasis^{56 100 101} models have been reported so far. Nevertheless, microfluidic technology has already contributed to some of the recent advances in understanding CRC pathophysiology. In 2015, Vacchelli *et al.* conducted a complex study to investigate molecular mechanisms involved in cancer cell-

immune cell interactions and their implications in the development of chemotherapy-induced antitumor immunity¹⁰². In one step of this work, a microfluidic device was used to confirm that formyl peptide receptor 1 (FPR1) plays an important role in allowing and stabilizing the interaction between dying cancer cells and human immune cells, a crucial step in the antitumor immunity development. Besides being used to highlight such molecular and biochemical signaling pathways in CRC, microfluidic instruments were used, here again, to investigate the biophysical and mechanical aspects related to this disease. Recently, Armistead *et al.*¹⁰³ used microfluidic platforms for studying the impact of different shear stress levels in three different CRC cell lines, SW480, HT29 and SW620. A leukemia cell line HL60 was also used as a circulatory cell model for comparison with the CRC cell lines¹⁰³. It was found that, under shear flow conditions, the metastatic cell line SW620 showed more deformation ability compared to the primary tumor-derived cell line SW480. This increased deformability has been shown to be related to an up-regulated expression of genes involved in cytoskeleton regulation¹⁰³. The two examples cited above clearly illustrate the implication of microfluidics in CRC research but do not constitute tumor-on-chip models *per se*. In the framework of CRC modeling, one of the best works to be mentioned was published in 2016 by Sobrino *et al.* In this study, colorectal, breast, and melanoma cancer cells were used to create vascularized tumor models⁹⁹. The tumor-on-a-chip design described in this work (Fig. 3A) consisted of three cell-culture chambers, delimited by two parallel microfluidic channels, with two media inlets and outlets. All these inlets and outlets were connected to a reservoir containing culture medium flowing across the microfluidic channels through the establishment of hydrostatic pressure gradient. To create a vascularized tumor model within this device, cancer cells (one type at a time), endothelial cells (Human endothelial colony forming cell-derived ECs (ECFC-ECs)) and stromal cells (Normal human lung fibroblasts (NHLFs)) were suspended in a fibrinogen solution. Thrombin was then added before the mixture was quickly loaded into the culture chambers and allowed for gelation. Within five to seven days, endothelial cells organized into a functional vascular network that merged with the outer channels and supported physiological flow. Among the cancer cells involved in this study, three CRC cell lines were used (SW480, SW620 and HCT116). Cancer cells were able to proliferate and form small spherical aggregates often in close proximity with the newly formed micro-capillaries. Interestingly, this platform maintained the specific phenotypic characteristics of the different cancer cell types: the SW480 non-invasive cell line formed tight structures while the SW620

metastatic cell line conserved its invasive growing profile. This tumor-on-a-chip device was also used to perform anticancer drug tests on the developed tumor models. For example, a routinely used drug combination in CRC treatment (5-Fluorouracyl, leucovorin, oxaliplatin) was assessed. The results confirmed its cytotoxic (rather than cytostatic) action on CRC cells and highlighted its low toxicity on the capillary network. In this model, one limitation could be the lack of mechanical constraints simulating digestive peristalsis. A complementary CRC-on-chip model was reported in 2021 by Strelez et al¹⁰⁴. It consisted of an epithelial-endothelial interface that could be submitted to peristaltic-like deformation. This device was used to study the early stages dissemination of CRC cancer cells namely intravasation. To investigate further CRC metastasis phases, one of the first microfluidic models was described by Skardal *et al.* in 2016¹⁰¹. It consisted of two connected microfluidic culture chambers (Fig. 3B). In one chamber, human intestine epithelial cells and HCT116 CRC cells (ratio 10:1) were used to simulate a primary tumor site. In the other chamber, a liver-mimicking structure was created by using human hepatoma cells (HepG2). In both cases, cells were suspended in a hydrogel and introduced into the microfluidic device. The hydrogel was photocrosslinked using UV-light, and fluid flow was generated across the microfluidic chip using micro-peristaltic pumps. After proliferation in the primary tumor site, HCT116 cells disseminated into the circulating media flow and reached the liver site where they formed secondary tumor aggregates. For comparison, the same procedure was conducted with another CRC cell line (SW480) which has less invasive potential than HCT116 cells. In this case, cells could grow in the primary site but never left it to spread elsewhere. This system was also used to study the impact of microenvironment mechanical properties on the metastatic behavior of CRC cells and to perform anticancer drug assays. In 2019, the same research team described an improved version of this metastasis-on-chip platform. It comprised a multi-organ-on-a-chip for the study of metastatic affinity of CRC cells⁵⁶. This device contained four metastasis units equidistant from a primary tumor site (Fig. 3C). To form the latter, HCT116 CRC cells were incorporated into hyaluronic acid-gelatin gel to create a tumor-like structure. The same hydrogel was used to create liver, lung, and endothelial-based structures in three different metastatic units. A cell-free structure was created in the fourth metastatic unit to serve as a control. In this platform, CRC cells were shown to have a higher metastatic preference for liver and lung constructs. One drawback of these promising systems is the lack of an *in vivo*-like endothelial barrier to study the intravasation and extravasation phenomena that are crucial steps in the

metastatic process. Overall, the analysis of the previous examples shows the difficulty of combining different metastasis steps in a single model. Creating a complete metastasis device with a primary and a secondary sites each comprising a functional endothelial barrier remains challenging.




Figure 3: Cancer-on-chip (COC) technology applications for colorectal cancer.

(A) (1): Schematic of the microdevice used to grow vascularized micro-tumors. This device was composed of two perfusion channels and three culture chambers. (2): Confocal microscopy imaging of the vascular network formed by endothelial cells (Lentivirally-transduced ECFC-EC, red) after 7 days of culture. This network could connect to the two microfluidic channels. (Scale bar: 200 μ m). Reproduced from⁹⁹, with permission from Nature Publishing Group. (B) Overview of the experimental setup used as metastatic model of colorectal cancer (1). Photography (top) and schematic (bottom) of this metastasis model (2). It included two chambers (G for gut and LI for liver). Blue arrows show the sense of culture medium flow; Red arrow show the sense of potential migration of cancer cells from the primary tumor site to the metastatic site¹⁰¹. (C) Multi-organ metastasis device including a primary tumor site (C for colon) which is equidistant from 4 metastatic sites: E for endothelial; Lu for lung; Li for liver and a control site (cell-free chamber). Reproduced from⁹⁴, with permission from MDPI.

3.5 Pancreatic cancer

Pancreas is a vital organ that performs a double role, an exocrine function through the secretion of digestive enzymes, and an endocrine function through the secretion of hormones

such as insulin and glucagon for blood sugar regulation¹⁰⁵. These two functions are related to different histological structures. Exocrine function is held by conical-shaped cells disposed around central lumens forming cell clusters named acini, separated by vascularized connective tissue¹⁰⁵. The exocrine part constitutes the largest part of the pancreatic parenchyma¹⁰⁵. It is also the birthplace of pancreatic ductal adenocarcinoma (PDAC), the most frequent tumor of the pancreas¹⁰⁶. This cancer has focused most of the researchers' attention on microfluidic modelling of pancreatic tumors.

One of the first works in this context was published by Drifka *et al.* in 2013, who used a microfluidic device to investigate the complex interplay between cancer cells and stroma elements¹⁰⁷. The model they described consisted of a microfluidic chamber with one outlet and three different inlets (one central and two side inlets) (Fig. 4A). PANC-1 pancreatic adenocarcinoma cells were suspended in an ECM-mimicking hydrogel (collagen-hyaluronic acid) and the suspension was introduced through the central inlet. Stromal cells (pancreatic stellate cells, PSC) were suspended in the same hydrogel and simultaneously introduced through the two side inlets. After hydrogel polymerization, a three-layered culture was obtained with a central tumor mass sandwiched between two stroma layers. This model was then used to assess the therapeutic response to the anticancer drug Paclitaxel. After exposure to Paclitaxel, cancer cells in the model showed reduced viability. Moreover, the specific structure of the stroma was disrupted. While this study focused on the interplay between cancer cells and stroma cells, endothelial cells have been included in other pancreatic cancer-on-a-chip models. For example, a recent work published in 2019 highlighted an important phenomenon called "endothelial ablation"¹⁰⁸ using a microfluidic device. This model consisted of a collagen matrix in which two parallel cylindrical channels were formed. One channel was lined with ECs to simulate a vascular capillary. The other channel mimicked a pancreatic duct and was seeded with primary mouse pancreatic cancer cells (PD7591) that formed an epithelial monolayer (Fig. 4B). A fetal bovine serum gradient in the vessel-like channel was then used to stimulate cancer cell migration through the collagen matrix. Under this stimulation, cancer cells were able to reach the vascular-like structure and penetrate its lumen after crossing the endothelial barrier. Moreover, it was shown that cancer cells do not just cross the vessel but partly occupy its lumen. In the vessel parts colonized by cancer cells, a high apoptotic tendency of endothelial cells, as well as the destruction of the collagen IV basal

membrane were observed. The authors used the term “*endothelial ablation*” to refer to this phenomenon. These findings were reproduced using other mouse and human pancreatic cancer cell lines and were also observable in *in vivo* PDAC models. Here, the use of a microfluidic device allowed to elucidate an important pathophysiological process. Endothelial ablation could indeed help explain why PDAC is highly invasive and at the same time poorly vascularized, which reduces its accessibility to systematically administered chemotherapy¹⁰⁸. Apart from endothelial ablation, other mechanisms involved in pancreatic cancer chemoresistance have been revealed through the use of microfluidic systems. In 2019, Kramer *et al*¹⁰⁹. investigated the effects of intratumoral pressure on S2-028 pancreatic cancer cell responses to gemcitabine (a frequently used cytotoxic molecule in advanced stage pancreatic cancer¹¹⁰). They found these cells to be significantly more resistant to gemcitabine when exposed to intratumoral-like interstitial flow in comparison with cells cultured in 2D. This enhanced drug resistance was attributed to an increased expression and activity of multi-drug resistance proteins¹⁰⁹. Along with other cancer types, pancreatic cancer is characterized by genetic heterogeneity and instability associated with a complex tumor microenvironment¹¹¹ making it even more difficult to realize *in vitro* relevant experimental platforms. Bradney *et al*. tried to capture part of this heterogeneity by incorporating murine PDAC cancer cells with different genomic subtypes into a microfluidic device¹¹¹. In the same context, Haque *et al*¹¹². designed a microfluidic platform to grow patient derived pancreas cancer organoids in the presence of key TME elements including stroma cells (pancreas stellate cells) and macrophages. This experimental platform was further used to highlight the stroma modulation of anticancer drug responses¹¹². These works are interesting attempts to better capture the tumor heterogeneity and its impact on drug responses. They are also additional examples to illustrate the interest of microfluidics in pancreas cancer modelling.




Figure 4: Application of cancer-on-chip technology for pancreatic cancer modelling.

(A) Microfluidic device used to study interactions between cancer cells (PANC-1) and stromal cells (PSC). An overall schematic of the device is shown in (1). The simultaneous introduction of cell-loaded hydrogels into the device is shown in (2): PANC-1 cell-loaded hydrogel (blue) was introduced through the middle inlet and PSC-loaded hydrogel (yellow) was introduced through the flanking inlets. As shown in (3), injection of culture medium (pink) through the flanking channels resulted in contraction of the three-layer cell construct. Cross section views of the process are shown in (4), (5) and (6). Reproduced from¹⁰⁷, with permission from Royal Society of Chemistry. (B) The device used to reveal endothelial ablation in pancreatic cancer. (1): A cross-section view of the device. (2): A confocal imaging of a section of the endothelial-lined channel showing its invasion by PD7591 cancer cells (i and ii). Endothelial cells (HUVECs) were marked with Anti-CD31 (red). PD7591 cells were labeled with FITC-conjugated anti-GFP (green fluorescent protein) antibody. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue). Reproduced from¹⁰⁸, with permission from American Association for the Advancement of Science.

3.6 Ovarian cancer

Ovary produces female gametes (ova) and female sex hormones (estrogens and progesterone). It consists of a cortical region, a central region (medulla) and a hilus¹¹³. The term ovarian cancer refers to several histologically and genetically distinct pathologies. High

grade serous ovarian cancer, also known as high grade serous carcinoma (HGSC)¹¹⁴, is the most common and severe form. It accounts for 70% to 80% of the mortality associated with all ovarian cancer subtypes¹¹⁵. This probably explains why HGSC focuses most efforts on terms of microfluidic modelling of ovarian cancer.

Nowadays, it is hypothesized that premalignant lesions originating from the fallopian tubes may be involved in the genesis of HGSC^{116 114}. To clarify this interplay, Fleszar *et al.* designed a microfluidic model of an ovarian cortical inclusion cyst (OCIC) to study its interactions with fallopian tube epithelial cells¹¹⁶. Before describing this OCIC model, we should remember that ovarian cortical inclusion cysts are cystic structures that form within the ovary when cells from the ovary surface epithelium (OSE) penetrate into the ovarian cortex after OSE rupture during ovulation¹¹⁴.

Before establishing their OCIC model, Fleszar *et al.*¹¹⁶ studied human ovarian sections and observed that a dense collagen band surrounds inclusion cysts with collagen fibers parallel to their boundaries. Then, they set up an *in vitro* OCIC experimental model consisting of a microfluidic cylindrical channel molded in a collagen-based hydrogel. This channel included a bottom large inlet, a top small inlet and two lateral inlets. Mouse fallopian tube epithelial cells (FTE) were then seeded in this OCIC model and formed a confluent monolayer over the channel surface. After this initial epithelialization phase, FTE cells spread into the collagen-based hydrogel showing an invasive behavior. Interestingly, the number of invading cells and their migration distance were influenced by the collagen type and concentration in the ECM-like hydrogel. The importance of ECM properties on cell behavior was thus demonstrated using a simple microfluidic device. While this study looks at early stages of HGSC development, other research teams have used microfluidic technology to develop metastatic models.

Indeed HGSC is a rapidly proliferating malignancy and it invades the peritoneal cavity often shortly after the apparition of the primary lesion¹¹⁷. This explains its late diagnosis and poor prognosis^{114,117}. Unlike most solid tumors, which usually spread by hematogenous or lymphatic routes¹¹⁸, ovarian cancer invades the abdominal cavity primarily through the peritoneal fluid. Cell aggregates (spheroids) derived from the primary lesion can circulate and further attach to secondary sites¹¹⁷. In an attempt to simulate this process, Li *et al.* used a microfluidic platform to reproduce the key structural and dynamic features of the peritoneum¹¹⁹. This “peritoneum-on-a-chip” device consisted of three parallel microfluidic

channels. Each channel was coated with fibronectin and seeded with primary human peritoneal mesothelial cells (HPMC) to form an epithelial monolayer on the bottom of its surface. SKOV-3 spheroids obtained in non-adherent 96-well plates were then introduced into the device. A syringe pump was used to apply physiologically relevant fluid flow across the microfluidic channels and cell spheroid behavior was observed over time. This simple model was far from capturing the *in vivo* complexity of the abdominal cavity but it already provided a good overview of microfluidics' potential to study ovarian cancer dissemination. Authors suggested improvements of their platform by incorporating other cell types to make it a more relevant experimental model for fundamental studies or for the development of new therapeutic tools. Other research teams have already reported the use of microfluidic platforms in the development of innovative therapeutic strategies. In one example, Wimalachandra *et al.* used a microfluidic experimental model to assess the efficacy and toxicity of anti-cancer nanoparticles¹²⁰. For discussing this example, we will first have to describe these nanoparticles. They were designed to amplify the anti-cancer immune response by specifically targeting tumor cells and increasing recruitment of immune cells into the tumor region. For this goal, silica core-shell nanoparticles (NPs) were conjugated with folic acid and loaded with CCL21 (a chemokine known to stimulate the migration of dendritic cells and cytotoxic T lymphocytes). To validate these NPs, the authors developed a microfluidic platform consisting of a central channel connected to two side channels. The central channel was filled with a fibrin hydrogel containing human ovarian carcinoma cells (OVCAR-3) to mimic a tumor compartment. The two side channels were coated with fibronectin and seeded with HUVECs to generate an endothelial barrier. CCL21 loaded or CCL21 free NPs were added in one of the side channels. In this same channel, immune cells were then introduced and their migration across the vascular compartment toward the tumor site was observed. In comparison with CCL21 free NPs, CCL21 loaded NPs significantly increased immune cell migration into the tumor-endothelial interface and the tumor compartment. Other experiments showed that these CCL21 loaded NPs had no hemolytic activity and no disturbing effect on the coagulation processes which allowed to consider an intravenous administration. One important advantage of this system was the presence of an endothelial-like barrier to study the trans-endothelial passage of nanoparticles. However, only cancer cells were used in the tumor area and other important actors in the TME such as fibroblasts were not represented in this model.

3.7. Brain cancers

Among primary brain malignances, glioblastoma (GBM) is the most frequent and aggressive¹²¹. COC technology has been widely investigated in GBM modeling both for fundamental pathophysiological studies and for drug evaluation¹²². In 2022, Alves et al reviewed glioblastoma microfluidic models that have been used to evaluate GBM related therapeutic strategies over the past 10 years. This provided a good overview of the diversity and the evolution of the developed GBM-on-chip platforms. While lithography was the predominant manufacturing method and PDMS the most frequently used material, the designs of GBM-on-chip devices strongly varied from one study to the other depending on the model's goals. Among GBM specificities, the presence of the Blood Brain Barrier (BBB) is of major importance as its precise role remains to be clarified¹²³. Du to their ability to simulate biological interfaces, microfluidic devices are particularly suitable to model the BBB for better understanding its implication in GBM pathophysiology and therapeutic outcomes. In this context, one interesting approach was described in 2022 by Straehla *et al.*¹²⁴. They described a GBM-on-chip model consisting of tumor spheroids cultured with vascular cells, astrocytes and pericytes that self-organized to form a functional BBB-like structure. This model was used to assess the transport of therapeutic nanoparticles through the BBB. In vivo studies were performed to validate the predictivity of this GBM-BBB microfluidic model¹²⁴.

3.8. Hepatic cancers

While few primary liver tumor-on-chip models have been reported^{125,126}, microfluidic technology has been widely exploited in the study of metastatic phenomena involving the liver^{55,127–129}. Moreover, being a crucial metabolic center, the impact of hepatic metabolism on the efficacy and toxicity of chemotherapy has also been studied using multi-site or multi-organ microfluidic models¹³⁰. In this context, the ability of microfluidic systems to combine multiple sites while linking them through physiological-like circulatory systems is of crucial importance as it allows to take a step further in the global modeling of the human organism *in vitro*¹³¹.

4. Challenges and future perspectives in microfluidic preclinical models

Although there has been a significant progress in the use of microfluidic technology for cancer modelling, further efforts should be undertaken not only to create more comprehensive models, but also to promote and accelerate their implementation at the industrial level. Though the analyses of the current state of the art, three main research areas can be indicated: (i) identifying and solving problems related to the fabrication and daily handling of microfluidic devices; (ii) addressing biological issues related to cancer-on-chip models; and (iii) accelerating the transfer from research to applications.

4.1 Fabrication and handling issues

Most OOC models are manufactured through soft photolithography process, which requires specific equipment, clean chambers, and qualified personnel. An interesting research perspective would be to develop alternative methods that are less restrictive and easier to implement while maintaining the precision and flexibility of photolithography. One recent attempt to address this problem was reported by Ferreira *et al*¹³². They described a rapid OOC manufacturing method based on xurography¹³². Xurography can be defined as the process in which the designed shape of each microfluidic channel is cut in a pre-cured thin PDMS layer. A cutting plotter was introduced to remove material from the PDMS layer to realize the desired shape. The layers were then bonded by plasma treatment for final assembly of the device. In contrast to soft lithography, this method does not require the prior fabrication of a mold. Nevertheless, PDMS layers with a minimum thickness of 200 μm should be used for a good manufacturing resolution¹³². In the same context, the use of 3D printing was also explored and may help to improve OOC manufacturing processes¹³³. Another research prospect would be the identification of new materials for the fabrication of microfluidic platforms. Currently, PDMS is considered to be the "golden standard" material for OOC devices due to its interesting properties such as easy handling, gas permeability and optical transparency¹³⁴. However, this material also has a high adsorption capacity for small hydrophobic molecules³¹. Therefore, it can bind therapeutic drugs, reduce their concentration, and affect their biological effect. In this context, Campbell *et al.* have recently reviewed materials that could be potential alternatives to PDMS for OOC production³¹. These

include elastomers, hydrogels, thermoplastic polymers, and inorganic materials³¹. Beyond manufacturing steps, the daily handling of microfluidic devices can also be challenging¹⁸ because of the need of specific and cumbersome materials, such as peristaltic pumps or syringe pump units. Air bubbles remain another big issue to overcome while carrying out experiments on microfluidic devices¹³.

4.2 Biological challenges

To consider COC application for the development of new anticancer molecules, a trade-off should be made between (i) their biological complexity and (ii) their ability to test multiple therapeutic molecules and multiple drug concentrations simultaneously. Indeed, the observation of current models shows that the above two parameters often evolve in opposite directions. In High throughput microfluidic devices, the biological part (tumor-like part) often consists of simple cancer cell structures without vascular network and without TME components^{62,135,136}. On the contrary, complex cancer-on-chip devices with vascularization and TME elements are often difficult to adapt for large-scale drug screening applications^{70,79}. High throughput thus remains a major challenge in current COC systems. An interesting attempt to combine sufficient biological complexity and high-throughput screening capability in a single device was reported by Phan *et al.*¹³⁷ They developed a microfluidic device comprising multiple tumor structures perfused by a functional vascular network. Cancer cells (HCT116) and stromal cells (human normal lung fibroblasts (NHLF)) were used to create the tumor structures. This platform was then used to assess efficacy and cancer cytotoxicity of multiple anticancer drugs including cytotoxic and anti-angiogenic molecules. While this system showed cell diversity (three cell categories) and large-scale drug screening applications, it was only used for short term assessment of drug effects (72 hours). Thus, an interesting research perspective would be to develop *in vitro* microphysiological systems that remain viable and functional over long term (several weeks to few months)¹³ to study the kinetics of drug impacts. The use of machine learning is also being investigated. Artificial intelligence (AI) technology can indeed be combined with the OOC devices to improve and optimize their high throughput screening ability^{138,139}. When developing OOC models, it is also crucial to identify the most appropriate cell source for the considered application. Overall, three main cell sources can be identified including primary cells, stem cells, and immortalized

cell lines¹⁴⁰. Primary cells are already differentiated and functional besides maintaining patient-specific cues. However, they are often available in limited number and difficult to be cultured *ex vivo* while keeping their specific phenotype¹⁴¹. Human induced pluripotent stem cells (HiPSC) can be generated from easily accessible dermal fibroblasts and can be differentiated into different cell-types¹⁴¹. They are thus interesting alternatives to primary cells when establishing patient-specific OOC based tumor models¹⁴⁰. Both primary cells and HiPSC present inter-donor variability which can affect result reproducibility. Using immortalized cell lines present some advantageous including cost effectiveness and availability. They also allow better reproducibility compared to primary cells¹⁴². Finally, while culturing multiple cell types in a single device is important to reflect *in vivo* cell diversity, a supplementary challenge is to set the culture medium composition for ensuring optimal growth and function for all these cell types.

4.3 Transfer acceleration from research to applications

Although several microfluidic based models have been reported¹³ and used for testing drugs and therapeutic responses^{143,144}, most of them remain at the proof-of-concept level and do not find tangible applications in pharmaceutical research and development industry. We believe that one of the best ways to accelerate the development of OOC technology is to intensify collaboration between research laboratories and pharmaceutical companies. To optimize R&D investments, pharmaceutical companies need to have clinically relevant information as early as possible while developing a new drug molecule. This information must concern both the efficacy and the safety of the drug candidate for guiding the development decisions. In this context, OOCs have been shown to accurately reproduce clinically observed vascular¹⁴⁵, hepatic¹⁴⁶ and renal¹⁴⁷ side effects of new molecules developed by pharmaceutical companies. A systematic use of OOCs will thus allow earlier detection of these major side effects. For that, reproducibility issues related to these OOC devices also need to be addressed. Many variability sources can affect OOCs including cell sources and manufacturing process¹⁴⁰. Manual manufacturing processes such as PDMS replica molding are very interesting for the development phases as they are versatile and cost-effective. However, hand-made microfluidic devices show important user dependency and laboratory dependency¹⁴⁰. Before considering large-scale use of OOCs, the automation of manufacturing

processes is therefore necessary. Beyond technical issues, the scientific community, in collaboration with industry and international organizations, should undertake the effort to standardize the OOC technology, i.e., identify models, manufacturing processes, and handling conditions that would be systematically used at the international level. Promising attempts in this sense have already been reported¹⁴⁰. Finally, we also believe that stricter regulation of animal use in pharmaceutical industry would also be a good boost to the development of the OOC technology. Beyond industry, OOC technology finds interesting applications in the daily medical practice especially for personalized medicine purposes in cancer treatment. OOC made up with patient specific cancer cells can be useful to evaluate therapeutic protocols for optimizing their efficacy and reducing their side effects before administration to the patient¹⁴⁸.

5. Conclusion

Innovative preclinical models based on 3D cell culture and microfluidic technology appear to be a relevant alternative to 2D cellular models whose reliability has been questioned by the high failure rate of new anticancer molecules. The aim of this work was to highlight the most important contributions in terms of cancer-on-chip (COC) models to provide the reader a global overview on the progress made recently, the current limitations of this technology and future research perspectives arising from them. Indeed, many research efforts are being undertaken for developing these models and it is sometimes difficult to find one's way considering the large number of works published each year and the lack of a clear and universal nomenclature. Therefore, more collaborative work is required in order to overcome the current technological challenges and accelerate larger-scale implementation of these new *in vitro* preclinical models.

Acknowledgements

We sincerely thank the Algerian government and the France University Institute for supporting this work.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*. 2021;71(3):209-249. doi:<https://doi.org/10.3322/caac.21660>
2. WHO outlines steps to save 7 million lives from cancer. Accessed May 10, 2021. <https://www.who.int/news/item/04-02-2020-who-outlines-steps-to-save-7-million-lives-from-cancer>
3. Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. *Clin Transl Med*. 2018;7. doi:10.1186/s40169-018-0185-6
4. Trujillo-de Santiago G, Flores-Garza BG, Tavares-Negrete JA, et al. The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors. *Materials (Basel)*. 2019;12(18). doi:10.3390/ma12182945
5. Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. *J Hematol Oncol*. 2018;11. doi:10.1186/s13045-018-0662-9
6. Kapałczyńska M, Kolenda T, Przybyła W, et al. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. *Arch Med Sci*. 2018;14(4):910-919. doi:10.5114/aoms.2016.63743
7. Vadivelu R, Kamble H, Shiddiky M, Nguyen NT. Microfluidic Technology for the Generation of Cell Spheroids and Their Applications. *Micromachines*. 2017;8(4):94. doi:10.3390/mi8040094
8. Joseph JS, Malindisa ST, Ntwasa M. *Two-Dimensional (2D) and Three-Dimensional (3D) Cell Culturing in Drug Discovery*. IntechOpen; 2018. doi:10.5772/intechopen.81552
9. Nath S, Devi GR. Three-Dimensional Culture Systems in Cancer Research: Focus on Tumor Spheroid Model. *Pharmacol Ther*. 2016;163:94-108. doi:10.1016/j.pharmthera.2016.03.013
10. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. *Am J Transl Res*. 2014;6(2):114-118.
11. Ravi M, Paramesh V, Kaviya SR, Anuradha E, Solomon FDP. 3D Cell Culture Systems: Advantages and Applications. *Journal of Cellular Physiology*. 2015;230(1):16-26. doi:<https://doi.org/10.1002/jcp.24683>
12. Hermida MA, Kumar JD, Schwarz D, et al. Three dimensional in vitro models of cancer: Bioprinting multilineage glioblastoma models. *Advances in Biological Regulation*. 2020;75:100658. doi:10.1016/j.jbior.2019.100658
13. Sontheimer-Phelps A, Hassell BA, Ingber DE. Modelling cancer in microfluidic human organs-on-chips. *Nat Rev Cancer*. 2019;19(2):65-81. doi:10.1038/s41568-018-0104-6
14. Suurmond CAE, Lasli S, van den Dolder FW, et al. In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells. *Advanced Healthcare Materials*. 2019;8(24):1901379. doi:10.1002/adhm.201901379

15. Ashammakhi N, Wesseling-Perry K, Hasan A, Elkhammas E, Zhang YS. Kidney-on-a-chip: untapped opportunities. *Kidney International*. 2018;94(6):1073-1086. doi:10.1016/j.kint.2018.06.034
16. Ashammakhi N, Elkhammas E, Hasan A. Translating advances in organ-on-a-chip technology for supporting organs. *Journal of Biomedical Materials Research Part B: Applied Biomaterials*. 2019;107(6):2006-2018. doi:10.1002/jbm.b.34292
17. Ashammakhi N, Nasiri R, Barros NR de, et al. Gut-on-a-chip: Current progress and future opportunities. *Biomaterials*. 2020;255:120196. doi:10.1016/j.biomaterials.2020.120196
18. Kimura H, Sakai Y, Fujii T. Organ/body-on-a-chip based on microfluidic technology for drug discovery. *Drug Metabolism and Pharmacokinetics*. 2018;33(1):43-48. doi:10.1016/j.dmpk.2017.11.003
19. Whitesides GM. The origins and the future of microfluidics. *Nature*. 2006;442(7101):368-373. doi:10.1038/nature05058
20. Martins JP, Torrieri G, Santos HA. The importance of microfluidics for the preparation of nanoparticles as advanced drug delivery systems. *Expert Opin Drug Deliv*. 2018;15(5):469-479. doi:10.1080/17425247.2018.1446936
21. Haeberle S, Zengerle R. Microfluidic platforms for lab-on-a-chip applications. *Lab Chip*. 2007;7(9):1094-1110. doi:10.1039/B706364B
22. Jiang Y, Wang PC, Locascio LE, Lee CS. Integrated Plastic Microfluidic Devices with ESI-MS for Drug Screening and Residue Analysis. *Anal Chem*. 2001;73(9):2048-2053. doi:10.1021/ac001474j
23. Bai Y, Gao M, Wen L, et al. Applications of Microfluidics in Quantitative Biology. *Biotechnology Journal*. 2018;13(5):1700170. doi:10.1002/biot.201700170
24. Boyd-Moss M, Baratchi S, Venere MD, Khoshmanesh K. Self-contained microfluidic systems: a review. *Lab Chip*. 2016;16(17):3177-3192. doi:10.1039/C6LC00712K
25. Leygeber M, Lindemann D, Sachs CC, et al. Analyzing Microbial Population Heterogeneity—Expanding the Toolbox of Microfluidic Single-Cell Cultivations. *Journal of Molecular Biology*. 2019;431(23):4569-4588. doi:10.1016/j.jmb.2019.04.025
26. Sonnen KF, Merten CA. Microfluidics as an Emerging Precision Tool in Developmental Biology. *Developmental Cell*. 2019;48(3):293-311. doi:10.1016/j.devcel.2019.01.015
27. Wu Q, Liu J, Wang X, et al. Organ-on-a-chip: recent breakthroughs and future prospects. *BioMedical Engineering OnLine*. 2020;19(1):9. doi:10.1186/s12938-020-0752-0
28. Faustino V, Catarino SO, Lima R, Minas G. Biomedical microfluidic devices by using low-cost fabrication techniques: A review. *Journal of Biomechanics*. 2016;49(11):2280-2292. doi:10.1016/j.jbiomech.2015.11.031
29. Giouroudi I, Keplinger F. Microfluidic Biosensing Systems Using Magnetic Nanoparticles. *IJMS*. 2013;14(9):18535-18556. doi:10.3390/ijms140918535

30. Zhu F, Baker D, Skommer J, Sewell M, Wlodkowic D. Real-time 2D visualization of metabolic activities in zebrafish embryos using a microfluidic technology. *Cytometry Part A*. 2015;87(5):446-450. doi:10.1002/cyto.a.22662
31. Campbell SB, Wu Q, Yazbeck J, Liu C, Okhovatian S, Radisic M. Beyond Polydimethylsiloxane: Alternative Materials for Fabrication of Organ-on-a-Chip Devices and Microphysiological Systems. *ACS Biomater Sci Eng*. 2021;7(7):2880-2899. doi:10.1021/acsbomaterials.0c00640
32. Radisic M, Loskill P. Beyond PDMS and Membranes: New Materials for Organ-on-a-Chip Devices. *ACS Biomater Sci Eng*. 2021;7(7):2861-2863. doi:10.1021/acsbomaterials.1c00831
33. Darabi MA, Khosrozadeh A, Wang Y, et al. An Alkaline Based Method for Generating Crystalline, Strong, and Shape Memory Polyvinyl Alcohol Biomaterials. *Advanced Science*. 2020;7(21):1902740. doi:10.1002/advs.201902740
34. Ding C, Chen X, Kang Q, Yan X. Biomedical Application of Functional Materials in Organ-on-a-Chip. *Front Bioeng Biotechnol*. 2020;8:823. doi:10.3389/fbioe.2020.00823
35. Alizadeh P, Soltani M, Tutar R, et al. Use of electroconductive biomaterials for engineering tissues by 3D printing and 3D bioprinting. *Essays in Biochemistry*. 2021;65(3):441-466. doi:10.1042/EBC20210003
36. Ehrlich DJ, Matsudaira P. Microfluidic devices for DNA analysis. *Trends Biotechnol*. 1999;17(8):315-319. doi:10.1016/s0167-7799(99)01310-4
37. Delamarche E, Bernard A, Schmid H, Michel B, Biebuyck H. Patterned delivery of immunoglobulins to surfaces using microfluidic networks. *Science*. 1997;276(5313):779-781. doi:10.1126/science.276.5313.779
38. Chiem NH, Harrison DJ. Microchip systems for immunoassay: an integrated immunoreactor with electrophoretic separation for serum theophylline determination. *Clin Chem*. 1998;44(3):591-598.
39. Figeys D, Gygi SP, McKinnon G, Aebersold R. An integrated microfluidics-tandem mass spectrometry system for automated protein analysis. *Anal Chem*. 1998;70(18):3728-3734. doi:10.1021/ac980320p
40. Leclerc E, Sakai Y, Fujii T. Microfluidic PDMS (polydimethylsiloxane) bioreactor for large-scale culture of hepatocytes. *Biotechnol Prog*. 2004;20(3):750-755. doi:10.1021/bp0300568
41. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting Organ-Level Lung Functions on a Chip. *Science*. 2010;328(5986):1662-1668. doi:10.1126/science.1188302
42. Migliore L, Coppedè F. Genetic and environmental factors in cancer and neurodegenerative diseases. *Mutation Research/Reviews in Mutation Research*. 2002;512(2-3):135-153. doi:10.1016/S1383-5742(02)00046-7
43. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. The Molecular Basis of Cancer-Cell Behavior. *Molecular Biology of the Cell 4th edition*. Published online 2002. Accessed January 4, 2022. <https://www.ncbi.nlm.nih.gov/books/NBK26902/>

44. Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. *Cancers (Basel)*. 2021;13(9):2053. doi:10.3390/cancers13092053
45. Fan F, Schimming A, Jaeger D, Podar K. Targeting the Tumor Microenvironment: Focus on Angiogenesis. *Journal of Oncology*. 2011;2012:e281261. doi:10.1155/2012/281261
46. Son B, Lee S, Youn H, Kim E, Kim W, Youn B. The role of tumor microenvironment in therapeutic resistance. *Oncotarget*. 2016;8(3):3933-3945. doi:10.18632/oncotarget.13907
47. Yi HG, Jeong YH, Kim Y, et al. A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy. *Nat Biomed Eng*. 2019;3(7):509-519. doi:10.1038/s41551-019-0363-x
48. Silva ACQ, Vilela C, Santos HA, Silvestre AJD, Freire CSR. Recent trends on the development of systems for cancer diagnosis and treatment by microfluidic technology. *Applied Materials Today*. 2020;18:100450. doi:10.1016/j.apmt.2019.100450
49. Liu P fei, Cao Y wei, Zhang S dong, et al. A bladder cancer microenvironment simulation system based on a microfluidic co-culture model. *Oncotarget*. 2015;6(35). doi:10.18632/oncotarget.6070
50. Truong DD, Kratz A, Park JG, et al. A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells. *Cancer Res*. 2019;79(12):3139-3151. doi:10.1158/0008-5472.CAN-18-2293
51. Aung A, Kumar V, Theprungsirikul J, Davey SK, Varghese S. An Engineered Tumor-on-a-Chip Device with Breast Cancer–Immune Cell Interactions for Assessing T-cell Recruitment. *Cancer Res*. 2020;80(2):263-275. doi:10.1158/0008-5472.CAN-19-0342
52. Ko J, Ahn J, Kim S, et al. Tumor spheroid-on-a-chip: a standardized microfluidic culture platform for investigating tumor angiogenesis. *Lab Chip*. 2019;19(17):2822-2833. doi:10.1039/C9LC00140A
53. Miller CP, Tsuchida C, Zheng Y, Himmelfarb J, Akilesh S. A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. *Neoplasia*. 2018;20(6):610-620. doi:10.1016/j.neo.2018.02.011
54. Buchanan CF, Verbridge SS, Vlachos PP, Rylander MN. Flow shear stress regulates endothelial barrier function and expression of angiogenic factors in a 3D microfluidic tumor vascular model. *Cell Adhesion & Migration*. 2014;8(5):517-524. doi:10.4161/19336918.2014.970001
55. Wang Y, Wu D, Wu G, et al. Metastasis-on-a-chip mimicking the progression of kidney cancer in the liver for predicting treatment efficacy. *Theranostics*. 2020;10(1):300-311. doi:10.7150/thno.38736
56. Aleman J, Skardal A. A multi-site metastasis-on-a-chip microphysiological system for assessing metastatic preference of cancer cells. *Biotechnol Bioeng*. 2019;116(4):936-944. doi:10.1002/bit.26871
57. Yankaskas CL, Thompson KN, Paul CD, et al. A microfluidic assay for the quantification of the metastatic propensity of breast-cancer specimens. *Nat Biomed Eng*. 2019;3(6):452-465. doi:10.1038/s41551-019-0400-9

58. Hao S, Ha L, Cheng G, et al. A Spontaneous 3D Bone-On-a-Chip for Bone Metastasis Study of Breast Cancer Cells. *Small*. 2018;14(12):1702787. doi:10.1002/smll.201702787
59. Mi S, Liu Z, Du Z, Yi X, Sun W. Three-dimensional microfluidic tumor–macrophage system for breast cancer cell invasion. *Biotechnology and Bioengineering*. 2019;116(7):1731-1741. doi:10.1002/bit.26961
60. Barisam M, Niavol FR, Kinj MA, Saidi MS, Ghanbarian H, Kashaninejad N. Enrichment of cancer stem-like cells by controlling oxygen, glucose and fluid shear stress in a microfluidic spheroid culture device. *Journal of Science: Advanced Materials and Devices*. 2022;7(2):100439. doi:10.1016/j.jsamd.2022.100439
61. Shen S, Zhang X, Zhang F, Wang D, Long D, Niu Y. Three-gradient constructions in a flow-rate insensitive microfluidic system for drug screening towards personalized treatment. *Talanta*. 2020;208:120477. doi:10.1016/j.talanta.2019.120477
62. Chang HC, Lin CH, Juang DS, et al. Multilayer architecture microfluidic network array for combinatorial drug testing on 3D-cultured cells. *Biofabrication*. Published online May 3, 2019. doi:10.1088/1758-5090/ab1f52
63. Weng KC, Kurokawa YK, Hajek BS, Paladin JA, Shirure VS, George SC. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity. *Tissue Engineering Part C: Methods*. 2020;26(1):44-55. doi:10.1089/ten.tec.2019.0248
64. Chen J, Liu CY, Wang X, et al. 3D printed microfluidic devices for circulating tumor cells (CTCs) isolation. *Biosensors and Bioelectronics*. 2020;150:111900. doi:10.1016/j.bios.2019.111900
65. Neves M, Azevedo R, Lima L, et al. Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications. *New Biotechnology*. 2019;49:77-87. doi:10.1016/j.nbt.2018.09.004
66. Varillas JI, Zhang J, Chen K, et al. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma. *Theranostics*. 2019;9(5):1417-1425. doi:10.7150/thno.28745
67. Sierra J, Marrugo-Ramírez J, Rodriguez-Trujillo R, Mir M, Samitier J. Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer. *Sensors (Basel)*. 2020;20(5). doi:10.3390/s20051317
68. Aimi F, Procopio MG, Alvarez Flores MT, et al. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study. *Virchows Arch*. 2019;475(3):313-323. doi:10.1007/s00428-019-02616-7
69. Benam KH, Mazur M, Choe Y, Ferrante TC, Novak R, Ingber DE. Human Lung Small Airway-on-a-Chip Protocol. In: Koledova Z, ed. *3D Cell Culture*. Vol 1612. Methods in Molecular Biology. Springer New York; 2017:345-365. doi:10.1007/978-1-4939-7021-6_25
70. Hassell BA, Goyal G, Lee E, et al. Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro. *Cell Reports*. 2017;21(2):508-516. doi:10.1016/j.celrep.2017.09.043

71. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non–Small Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. *J Thorac Oncol*. 2015;10(7):974-984. doi:10.1097/JTO.0000000000000551
72. Guo Z, Song J, Hao J, et al. M2 macrophages promote NSCLC metastasis by upregulating CRYAB. *Cell Death Dis*. 2019;10(6):377. doi:10.1038/s41419-019-1618-x
73. Yu T, Guo Z, Fan H, et al. Cancer-associated fibroblasts promote non-small cell lung cancer cell invasion by upregulation of glucose-regulated protein 78 (GRP78) expression in an integrated bionic microfluidic device. *Oncotarget*. 2016;7(18):25593-25603. doi:10.18632/oncotarget.8232
74. Xu Z, Li E, Guo Z, et al. Design and Construction of a Multi-Organ Microfluidic Chip Mimicking the in vivo Microenvironment of Lung Cancer Metastasis. *ACS Appl Mater Interfaces*. 2016;8(39):25840-25847. doi:10.1021/acsami.6b08746
75. Liu W, Song J, Du X, et al. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model. *Acta Biomaterialia*. 2019;91:195-208. doi:10.1016/j.actbio.2019.04.053
76. Jiang L, Ivich F, Tahsin S, et al. Human stroma and epithelium co-culture in a microfluidic model of a human prostate gland. *Biomicrofluidics*. 2019;13(6):064116. doi:10.1063/1.5126714
77. Tian BR, Lin WF, Zhang Y. Effects of biomechanical forces on the biological behavior of cancer stem cells. *J Cancer*. 2021;12(19):5895-5902. doi:10.7150/jca.60893
78. Ao M, Brewer BM, Yang L, et al. Stretching Fibroblasts Remodels Fibronectin and Alters Cancer Cell Migration. *Sci Rep*. 2015;5. doi:10.1038/srep08334
79. Choi Y, Hyun E, Seo J, et al. A microengineered pathophysiological model of early-stage breast cancer. *Lab Chip*. 2015;15(16):3350-3357. doi:10.1039/c5lc00514k
80. Virumbrales-Muñoz M, Livingston MK, Farooqui M, Skala MC, Beebe DJ, Ayuso JM. Development of a Microfluidic Array to Study Drug Response in Breast Cancer. *Molecules*. 2019;24(23). doi:10.3390/molecules24234385
81. Chen Y, Gao D, Wang Y, Lin S, Jiang Y. A novel 3D breast-cancer-on-chip platform for therapeutic evaluation of drug delivery systems. *Analytica Chimica Acta*. 2018;1036:97-106. doi:10.1016/j.aca.2018.06.038
82. Eslami Amirabadi H, Tuerlings M, Hollestelle A, et al. Characterizing the invasion of different breast cancer cell lines with distinct E-cadherin status in 3D using a microfluidic system. *Biomed Microdevices*. 2019;21(4). doi:10.1007/s10544-019-0450-5
83. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. *Nat Rev Cancer*. 2007;7(9):659-672. doi:10.1038/nrc2193
84. Devadas D, Moore TA, Walji N, Young EWK. A microfluidic mammary gland coculture model using parallel 3D lumens for studying epithelial-endothelial migration in breast cancer. *Biomicrofluidics*. 2019;13(6):064122. doi:10.1063/1.5123912
85. Cowell CF, Weigelt B, Sakr RA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: Revisited. *Mol Oncol*. 2013;7(5):859-869. doi:10.1016/j.molonc.2013.07.005

86. Nagaraju S, Truong D, Mouneimne G, Nikkhah M. Microfluidic Tumor–Vascular Model to Study Breast Cancer Cell Invasion and Intravasation. *Advanced Healthcare Materials*. 2018;7(9):1701257. doi:10.1002/adhm.201701257
87. Harrell JC, Pfefferle AD, Zalles N, et al. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. *Clin Exp Metastasis*. 2014;31(1):33-45. doi:10.1007/s10585-013-9607-4
88. Mei X, Middleton K, Shim D, et al. Microfluidic platform for studying osteocyte mechanoregulation of breast cancer bone metastasis. *Integrative Biology*. 2019;11(4):119-129. doi:10.1093/intbio/zyz008
89. Lanz HL, Saleh A, Kramer B, et al. Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform. *BMC Cancer*. 2017;17. doi:10.1186/s12885-017-3709-3
90. Pradhan S, Smith AM, Garson CJ, et al. A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy. *Sci Rep*. 2018;8. doi:10.1038/s41598-018-21075-9
91. GhavamiNejad A, Ashammakhi N, Wu XY, Khademhosseini A. Crosslinking Strategies for 3D Bioprinting of Polymeric Hydrogels. *Small*. 2020;16(35):2002931. doi:10.1002/smll.202002931
92. Wu Q, Li B, Li Z, Li J, Sun S, Sun S. Cancer-associated adipocytes: key players in breast cancer progression. *Journal of Hematology & Oncology*. 2019;12(1):95. doi:10.1186/s13045-019-0778-6
93. Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. *Frontiers in Oncology*. 2021;11. Accessed June 14, 2022. <https://www.frontiersin.org/article/10.3389/fonc.2021.610303>
94. Imparato G, Urciuolo F, Netti PA. Organ on Chip Technology to Model Cancer Growth and Metastasis. *Bioengineering*. 2022;9(1):28. doi:10.3390/bioengineering9010028
95. Zuchowska A, Skorupska S. Multi-organ-on-chip approach in cancer research. *Organs-on-a-Chip*. 2022;4:100014. doi:10.1016/j.ooc.2021.100014
96. Winter M, Cai Z, Winkler K, et al. Circulating tumour cell RNA characterisation from colorectal cancer patient blood after inertial microfluidic enrichment. *MethodsX*. 2019;6:1512-1520. doi:10.1016/j.mex.2019.06.012
97. Ribeiro-Samy S, Oliveira MI, Pereira-Veiga T, et al. Fast and efficient microfluidic cell filter for isolation of circulating tumor cells from unprocessed whole blood of colorectal cancer patients. *Sci Rep*. 2019;9. doi:10.1038/s41598-019-44401-1
98. Su W, Yu H, Jiang L, Chen W, Li H, Qin J. Integrated Microfluidic Device for Enrichment and Identification of Circulating Tumor Cells from the Blood of Patients with Colorectal Cancer. *Dis Markers*. 2019;2019. doi:10.1155/2019/8945974
99. Sobrino A, Phan DTT, Datta R, et al. 3D microtumors in vitro supported by perfused vascular networks. *Sci Rep*. 2016;6. doi:10.1038/srep31589

100. Ahn J, Lim J, Jusoh N, et al. 3D Microfluidic Bone Tumor Microenvironment Comprised of Hydroxyapatite/Fibrin Composite. *Front Bioeng Biotechnol.* 2019;7. doi:10.3389/fbioe.2019.00168
101. Skardal A, Devarasetty M, Forsythe S, Atala A, Soker S. A Reductionist Metastasis-on-a-Chip Platform for In Vitro Tumor Progression Modeling and Drug Screening. *Biotechnol Bioeng.* 2016;113(9):2020-2032. doi:10.1002/bit.25950
102. Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. *Science.* 2015;350(6263):972-978. doi:10.1126/science.aad0779
103. Armistead FJ, Gala De Pablo J, Gadêlha H, Peyman SA, Evans SD. Physical Biomarkers of Disease Progression: On-Chip Monitoring of Changes in Mechanobiology of Colorectal Cancer Cells. *Sci Rep.* 2020;10. doi:10.1038/s41598-020-59952-x
104. Strelez C, Chilakala S, Ghaffarian K, et al. Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread. *iScience.* 2021;24(5). doi:10.1016/j.isci.2021.102509
105. Henry BM, Skinningsrud B, Saganiak K, Pękala PA, Walocha JA, Tomaszewski KA. Development of the human pancreas and its vasculature — An integrated review covering anatomical, embryological, histological, and molecular aspects. *Annals of Anatomy - Anatomischer Anzeiger.* 2019;221:115-124. doi:10.1016/j.aanat.2018.09.008
106. Gallmeier E, Gress TM. Duktale Adenokarzinom des Pankreas. *Internist.* 2018;59(8):805-822. doi:10.1007/s00108-018-0460-z
107. Drifka CR, Eliceiri KW, Weber SM, Kao WJ. A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. *Lab Chip.* 2013;13(19):3965-3975. doi:10.1039/c3lc50487e
108. Nguyen DHT, Lee E, Alimperti S, et al. A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling. *Sci Adv.* 2019;5(8). doi:10.1126/sciadv.aav6789
109. Kramer B, Haan L de, Vermeer M, et al. Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins. *Int J Mol Sci.* 2019;20(18). doi:10.3390/ijms20184647
110. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *JCO.* 2007;25(16):2212-2217. doi:10.1200/JCO.2006.09.0886
111. Bradney MJ, Venis SM, Yang Y, Konieczny SF, Han B. A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma. *Small.* 2020;16(10):1905500. doi:10.1002/sml.201905500
112. Haque MR, Wessel CR, Leary DD, Wang C, Bhushan A, Bishehsari F. Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment. *Microsyst Nanoeng.* 2022;8(1):1-13. doi:10.1038/s41378-022-00370-6
113. Clement PB. Anatomy and Histology of the Ovary. :33.

114. Kim J, Park EY, Kim O, et al. Cell Origins of High-Grade Serous Ovarian Cancer. *Cancers (Basel)*. 2018;10(11). doi:10.3390/cancers10110433
115. Lisio MA, Fu L, Goyeneche A, Gao Z hua, Telleria C. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. *Int J Mol Sci*. 2019;20(4). doi:10.3390/ijms20040952
116. Fleszar AJ, Walker A, Porubsky V, et al. The Extracellular Matrix of Ovarian Cortical Inclusion Cysts Modulates Invasion of Fallopian Tube Epithelial Cells. *APL Bioeng*. 2018;2(3). doi:10.1063/1.5022595
117. Lengyel E. Ovarian Cancer Development and Metastasis. *Am J Pathol*. 2010;177(3):1053-1064. doi:10.2353/ajpath.2010.100105
118. Lacave R, Larsen CJ, Robert J. *Cancérologie fondamentale*. J. Libbey-Eurotext; 2005.
119. Li SS, Ip CKM, Tang MYH, et al. Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice. *J Vis Exp*. 2017;(120). doi:10.3791/55337
120. Wimalachandra DC, Li Y, Liu J, et al. Microfluidic-Based Immunomodulation of Immune Cells Using Upconversion Nanoparticles in Simulated Blood Vessel–Tumor System. *ACS Appl Mater Interfaces*. 2019;11(41):37513-37523. doi:10.1021/acsami.9b15178
121. Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. In: De Vleeschouwer S, ed. *Glioblastoma*. Codon Publications; 2017. Accessed June 9, 2022. <http://www.ncbi.nlm.nih.gov/books/NBK470003/>
122. Ustun M, Rahmani Dabbagh S, Ilci IS, Bagci-Onder T, Tasoglu S. Glioma-on-a-Chip Models. *Micromachines (Basel)*. 2021;12(5):490. doi:10.3390/mi12050490
123. Sarkaria JN, Hu LS, Parney IF, et al. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. *Neuro Oncol*. 2018;20(2):184-191. doi:10.1093/neuonc/nox175
124. Straehla JP, Hajal C, Safford HC, et al. A predictive microfluidic model of human glioblastoma to assess trafficking of blood–brain barrier-penetrant nanoparticles. *Proceedings of the National Academy of Sciences*. 2022;119(23):e2118697119. doi:10.1073/pnas.2118697119
125. Lu S, Cuzzucoli F, Jiang J, et al. Development of a biomimetic liver tumor-on-a-chip model based on decellularized liver matrix for toxicity testing. *Lab Chip*. 2018;18(22):3379-3392. doi:10.1039/c8lc00852c
126. Ozkan A, Ghouseifam N, Hoopes PJ, Yankeelov TE, Rylander MN. In vitro vascularized liver and tumor tissue microenvironments on a chip for dynamic determination of nanoparticle transport and toxicity. *Biotechnol Bioeng*. 2019;116(5):1201-1219. doi:10.1002/bit.26919
127. Kim J, Lee C, Kim I, et al. Three-Dimensional Human Liver-Chip Emulating Premetastatic Niche Formation by Breast Cancer-Derived Extracellular Vesicles. *ACS Nano*. 2020;14(11):14971-14988. doi:10.1021/acsnano.0c04778
128. Zheng L, Wang B, Sun Y, et al. An Oxygen-Concentration-Controllable Multiorgan Microfluidic Platform for Studying Hypoxia-Induced Lung Cancer-Liver Metastasis and Screening Drugs. *ACS Sens*. 2021;6(3):823-832. doi:10.1021/acssensors.0c01846

129. Khazali AS, Clark AM, Wells A. A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms. *Stem Cell Rev Rep*. 2017;13(3):364-380. doi:10.1007/s12015-017-9735-3
130. Soltantabar P, Calubaquib EL, Mostafavi E, Ghazavi A, Stefan MC. Heart/liver-on-a-chip as a model for the evaluation of cardiotoxicity induced by chemotherapies. *Organs-on-a-Chip*. 2021;3:100008. doi:10.1016/j.ooc.2021.100008
131. Kimura H, Ikeda T, Nakayama H, Sakai Y, Fujii T. An On-Chip Small Intestine–Liver Model for Pharmacokinetic Studies. *SLAS Technology*. 2015;20(3):265-273. doi:10.1177/2211068214557812
132. Ferreira DA, Rothbauer M, Conde JP, Ertl P, Oliveira C, Granja PL. A Fast Alternative to Soft Lithography for the Fabrication of Organ-on-a-Chip Elastomeric-Based Devices and Microactuators. *Advanced Science*. 2021;8(8):2003273. doi:10.1002/advs.202003273
133. Ozbolat V, Dey M, Ayan B, Povilianskas A, Demirel MC, Ozbolat IT. 3D Printing of PDMS Improves Its Mechanical and Cell Adhesion Properties. *ACS Biomater Sci Eng*. 2018;4(2):682-693. doi:10.1021/acsbomaterials.7b00646
134. Carter SSD, Atif AR, Kadekar S, et al. PDMS leaching and its implications for on-chip studies focusing on bone regeneration applications. *Organs-on-a-Chip*. 2020;2:100004. doi:10.1016/j.ooc.2020.100004
135. Khot MI, Levenstein MA, de Boer GN, et al. Characterising a PDMS based 3D cell culturing microfluidic platform for screening chemotherapeutic drug cytotoxic activity. *Sci Rep*. 2020;10(1):15915. doi:10.1038/s41598-020-72952-1
136. Fan Y, Nguyen DT, Akay Y, Xu F, Akay M. Engineering a Brain Cancer Chip for High-throughput Drug Screening. *Sci Rep*. 2016;6:25062. doi:10.1038/srep25062
137. Phan DTT, Wang X, Craver BM, et al. A vascularized and perfused organ-on-a-chip platform for large-scale drug screening applications. *Lab Chip*. 2017;17(3):511-520. doi:10.1039/C6LC01422D
138. Fetah KL, DiPardo BJ, Kongadzem EM, et al. Cancer Modeling-on-a-Chip with Future Artificial Intelligence Integration. *Small*. 2019;15(50):e1901985. doi:10.1002/smll.201901985
139. Elmusrati M, Ashammakhi N. Cancer-on-a-Chip and Artificial Intelligence: Tomorrow's Cancer Management. *Journal of Craniofacial Surgery*. 2018;29(7):1682-1683. doi:10.1097/SCS.0000000000004703
140. Leung CM, de Haan P, Ronaldson-Bouchard K, et al. A guide to the organ-on-a-chip. *Nat Rev Methods Primers*. 2022;2(1):1-29. doi:10.1038/s43586-022-00118-6
141. Tan B, Gan S, Wang X, Liu W, Li X. Applications of 3D bioprinting in tissue engineering: advantages, deficiencies, improvements, and future perspectives. *J Mater Chem B*. 2021;9(27):5385-5413. doi:10.1039/D1TB00172H
142. Kaur G, Dufour JM. Cell lines. *Spermatogenesis*. 2012;2(1):1-5. doi:10.4161/spmg.19885
143. Jiang X, Ren L, Tebon P, et al. Cancer-on-a-Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions. *Small*. 2021;17(7):2004282. doi:10.1002/smll.202004282

144. Ashammakhi N, Darabi MA, Çelebi-Saltik B, et al. Microphysiological Systems: Next Generation Systems for Assessing Toxicity and Therapeutic Effects of Nanomaterials. *Small Methods*. 2020;4(1):1900589. doi:10.1002/smtd.201900589
145. Barrile R, van der Meer AD, Park H, et al. Organ-on-Chip Recapitulates Thrombosis Induced by an anti-CD154 Monoclonal Antibody: Translational Potential of Advanced Microengineered Systems. *Clinical Pharmacology & Therapeutics*. 2018;104(6):1240-1248. doi:10.1002/cpt.1054
146. Jang KJ, Otieno MA, Ronxhi J, et al. Reproducing human and cross-species drug toxicities using a Liver-Chip. *Sci Transl Med*. 2019;11(517):eaax5516. doi:10.1126/scitranslmed.aax5516
147. Nieskens TTG, Magnusson O, Andersson P, Söderberg M, Persson M, Sjögren AK. Nephrotoxic antisense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip. *Arch Toxicol*. 2021;95(6):2123-2136. doi:10.1007/s00204-021-03062-8
148. Ashammakhi NA, Elzagheid A. Organ-on-a-Chip: New Tool for Personalized Medicine. *J Craniofac Surg*. 2018;29(4):823-824. doi:10.1097/SCS.0000000000004604